Bleomycin sclerotherapy in congenital lymphatic and vascular malformations of head and neck.
Bleomycin is an established antineoplastic drug, but recently some attempts were made to inject it locally as a sclerosing agent in cases of congenital lymphatic malformations. We present the outcome of this treatment modality tried on 10 paediatric cases of whom 9 had such malformation in the cervical region and one in the parotid region. Seven of these cases had congenital lymphatic malformation while three had haemodynamically less active congenital vascular malformation. All these children were subjected to percutaneous intralesional administration of bleomycin. The size of swelling reduced by 50% or more in seven patients out of which three showed complete or near complete response. There were no major deleterious side effects.
Mathur
Neeraj N
NN
Department of ENT, Lady Hardinge Medical College and associated Smt. Sucheta Kriplani and Kalawati Saran Children's Hospital, New Delhi 110001, India. nnm@vsnl.com
Rana
Indu
I
Bothra
Rajendra
R
Dhawan
Rajiv
R
Kathuria
Geeta
G
Pradhan
Tapaswini
T
D000279:Administration, Cutaneous; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001165:Arteriovenous Malformations / Q000628:therapy*; D001761:Bleomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006257:Head / Q000098:blood supply / Q000473:pathology; D006258:Head and Neck Neoplasms / Q000151:congenital / Q000628:therapy*; D006801:Humans; D007223:Infant; D015552:Injections, Intralesional; D018191:Lymphangioma, Cystic / Q000151:congenital / Q000628:therapy*; D008297:Male; D009333:Neck / Q000098:blood supply / Q000473:pathology; D015911:Sclerotherapy / Q000379:methods*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001761:Bleomycin